SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NRx Pharmaceuticals, Inc, of Class Action Lawsuit and Upcoming Deadline – NRXP; NRXPW – QNT Press Release

[ad_1]

NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ:NRXPNRXPW)) and certain of its officers. The class action, filed in the United States District Court for the District of Delaware, and docketed under 22-cv-00066, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired NRx securities between June 1, 2021 and November 4, 2021, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased or otherwise acquired NRx during the Class Period, you have until March 21, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at …

Full story available on Benzinga.com

[ad_2]

Source link

Recommended For You

About the Author: News Center